TY - JOUR
T1 - Integrin β3 Overexpression Suppresses Tumor Growth in a Human Model of Gliomagenesis
T2 - Implications for the Role of β3 Overexpression in Glioblastoma Multiforme
AU - Kanamori, Masayuki
AU - Vanden Berg, Scott R.
AU - Bergers, Gabriele
AU - Berger, Mitchel S.
AU - Pieper, Russell O.
PY - 2004/4/15
Y1 - 2004/4/15
N2 - αVβ3 integrin complexes are overexpressed in the growing, invading margins of human glioblastoma multiforme (GBM) and in the GBM vasculature, suggesting a key role for αVβ3 in GBM growth and invasion, The function of αVβ3 complexes in tumor formation, however, has been challenged by studies showing that loss of αVβ3 expression (via loss of β3) in the host vasculature enhances, rather than suppresses, the growth of s.c, implanted carcinomas. To directly address the role of tumor-specific αVβ3 overexpression in glioma formation, we increased αVβ3 expression (via overexpression of a wild-type or constitutively activated β3) in human astrocytes genetically modified to form anaplastic astrocytoma-like tumors (Ras cells) on intracranial injection in rats. Overexpression of β3 selectively increased levels of αVβ3 integrin complexes, but had no effect on anchorage-dependent or -independent growth in vitro. After intracranial injection, however, the Ras + β3 cells formed fewer and smaller tumors than did Ras cells. Similarly, Ras-transformed mouse astrocytes that were derived from control animals formed smaller intracranial tumors than those derived from β3 knockout animals. Although tumors formed by human Ras and Ras + β3 cells were similar in blood vessel density, Ras + β3 tumors had smaller, pericyte-depleted vessels and were significantly more hypoxic, suggesting a β3-mediated vascular defect. The growth-suppressive actions of β3, however, could be overcome by stimulation of pathways (Akt or vascular endothelial growth factor) commonly activated in GBM. These results show that tumor-specific αVβ3 overexpression has growth-suppressive effects in gliomas, but that these deleterious effects are mitigated by alterations common to αVβ 3-overexpressing GBM.
AB - αVβ3 integrin complexes are overexpressed in the growing, invading margins of human glioblastoma multiforme (GBM) and in the GBM vasculature, suggesting a key role for αVβ3 in GBM growth and invasion, The function of αVβ3 complexes in tumor formation, however, has been challenged by studies showing that loss of αVβ3 expression (via loss of β3) in the host vasculature enhances, rather than suppresses, the growth of s.c, implanted carcinomas. To directly address the role of tumor-specific αVβ3 overexpression in glioma formation, we increased αVβ3 expression (via overexpression of a wild-type or constitutively activated β3) in human astrocytes genetically modified to form anaplastic astrocytoma-like tumors (Ras cells) on intracranial injection in rats. Overexpression of β3 selectively increased levels of αVβ3 integrin complexes, but had no effect on anchorage-dependent or -independent growth in vitro. After intracranial injection, however, the Ras + β3 cells formed fewer and smaller tumors than did Ras cells. Similarly, Ras-transformed mouse astrocytes that were derived from control animals formed smaller intracranial tumors than those derived from β3 knockout animals. Although tumors formed by human Ras and Ras + β3 cells were similar in blood vessel density, Ras + β3 tumors had smaller, pericyte-depleted vessels and were significantly more hypoxic, suggesting a β3-mediated vascular defect. The growth-suppressive actions of β3, however, could be overcome by stimulation of pathways (Akt or vascular endothelial growth factor) commonly activated in GBM. These results show that tumor-specific αVβ3 overexpression has growth-suppressive effects in gliomas, but that these deleterious effects are mitigated by alterations common to αVβ 3-overexpressing GBM.
UR - http://www.scopus.com/inward/record.url?scp=2642533612&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=2642533612&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-03-3354
DO - 10.1158/0008-5472.CAN-03-3354
M3 - Article
C2 - 15087390
AN - SCOPUS:2642533612
SN - 0008-5472
VL - 64
SP - 2751
EP - 2758
JO - Cancer Research
JF - Cancer Research
IS - 8
ER -